Skip to Content

Pulzium Approval Status

Pulzium IV (tedisamil) is a class III anti-arrhythmic drug in the later phase of clinical development for the treatment of recent onset atrial fibrillation or atrial flutter.

Development Status and FDA Approval Process for Pulzium

Dec 13, 2007Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Sep 26, 2007Solvay Pharmaceuticals, Inc. Announces FDA Extension of Tedisamil PDUFA Date
Apr 25, 2007Solvay Pharmaceuticals Files Tedisamil, a New Cardiometabolic Product for the Treatment of Atrial Fibrillation and Atrial Flutter

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.